Covered recipient · General Payments record
RANA R MCKAY
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$140,620.16
75 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $72,109.25 | 38 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,870.00 | 2 |
| Travel and Lodging | $21,961.17 | 11 |
| Honoraria | $4,290.00 | 1 |
| Food and Beverage | $1,389.74 | 23 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme LLC | $71,390.71 | 17 |
| AstraZeneca UK Limited | $14,925.00 | 5 |
| Bayer Healthcare Pharmaceuticals Inc. | $11,023.00 | 10 |
| Daiichi Sankyo Inc. | $10,667.33 | 7 |
| Novartis Pharmaceuticals Corporation | $6,800.00 | 3 |
| E.R. Squibb & Sons, L.L.C. | $6,674.67 | 10 |
| PFIZER INC. | $5,500.00 | 1 |
| Exelixis Inc. | $5,264.02 | 7 |
| AstraZeneca Pharmaceuticals LP | $2,662.84 | 6 |
| Aveo Pharmaceuticals, Inc. | $2,220.00 | 1 |
| Janssen Research & Development, LLC | $2,077.90 | 3 |
| Janssen Scientific Affairs, LLC | $1,125.00 | 1 |
| Sumitomo Pharma America, Inc. | $106.45 | 1 |
| INTUITIVE SURGICAL, INC. | $96.58 | 1 |
| Blue Earth Diagnostics Limited | $66.25 | 1 |
| Eisai Inc. | $20.41 | 1 |
Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RANA R MCKAY
NPI 1306013610 · CMS profile ID 541869
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SAN DIEGO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1306013610?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RANA R MCKAY, NPI 1306013610, CMS profile ID 541869. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306013610?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). RANA R MCKAY, NPI 1306013610, CMS profile ID 541869. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306013610?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- RANA R MCKAY, NPI 1306013610, CMS profile ID 541869, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1306013610?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
75 matching records · $140,620.16 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–75 of 75.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Research & Development, LLC | $127.90 | 05/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077587447 | CMS |
| Merck Sharp & Dohme LLC | $150.00 | 04/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141552228 | CMS |
| Merck Sharp & Dohme LLC | $15,860.00 | 04/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141552232 | CMS |
| AstraZeneca UK Limited | $3,767.50 | 04/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093926997 | CMS |
| Merck Sharp & Dohme LLC | $8,050.36 | 04/17/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141667010 | CMS |
| Merck Sharp & Dohme LLC | $686.15 | 04/17/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141667012 | CMS |
| Merck Sharp & Dohme LLC | $279.84 | 04/17/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141667014 | CMS |
| Merck Sharp & Dohme LLC | $2,135.00 | 04/03/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141552002 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $702.00 | 03/21/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086131916 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $351.00 | 03/21/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086173486 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $702.00 | 03/21/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086233804 | CMS |
| AstraZeneca UK Limited | $2,055.00 | 03/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1094034357 | CMS |
| Novartis Pharmaceuticals Corporation | $1,600.00 | 03/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087151260 | CMS |
| Eisai Inc. | $20.41 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110775159 | CMS |
| Merck Sharp & Dohme LLC | $2,440.00 | 02/12/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141552996 | CMS |
| Merck Sharp & Dohme LLC | $610.00 | 02/12/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141552998 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,860.00 | 02/07/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101238686 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,860.00 | 02/06/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101238688 | CMS |
| E.R. Squibb & Sons, L.L.C. | $134.99 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101238714 | CMS |
| E.R. Squibb & Sons, L.L.C. | $29.99 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101238746 | CMS |
| Exelixis Inc. | $136.78 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138564284 | CMS |
| E.R. Squibb & Sons, L.L.C. | $134.70 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101238716 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.82 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101238718 | CMS |
| INTUITIVE SURGICAL, INC. | $96.58 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137117376 | CMS |
| Sumitomo Pharma America, Inc. | $106.45 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148888839 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $13,238.30 | 9 |
| PY2025 | Principal investigator | $4,323,458.05 | 242 |
| PY2024 | Recipient | $3,352.89 | 4 |
| PY2024 | Principal investigator | $3,527,490.91 | 155 |
| PY2023 | Principal investigator | $2,840,835.77 | 138 |
| PY2022 | Recipient | $1,449.34 | 5 |
| PY2022 | Principal investigator | $1,325,471.04 | 117 |
| PY2021 | Principal investigator | $997,595.76 | 89 |
| PY2020 | Principal investigator | $1,293,611.44 | 109 |
| PY2019 | Principal investigator | $444,496.16 | 30 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
251 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,261.78 | 12/31/2025 | Non-covered Recipient Entity Moores Cancer Center | A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01 | No dispute reported | 06/30/2026 | 1232922368 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,433.80 | 12/31/2025 | Non-covered Recipient Entity University of California San Diego Moores Cancer Center | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies | No dispute reported | 06/30/2026 | 1232931462 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,951.29 | 12/31/2025 | Non-covered Recipient Entity UC San Diego | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First | No dispute reported | 06/30/2026 | 1232934812 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $317,789.36 | 12/31/2025 | Non-covered Recipient Entity UC San Diego | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First | No dispute reported | 06/30/2026 | 1232934814 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,014.20 | 12/31/2025 | Non-covered Recipient Entity Moores Cancer Center-Clinical Trials Office- Genitourinary | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232934945 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $857.93 | 12/31/2025 | Non-covered Recipient Entity UC SAN DIEGO HEALTH BLOOD DRAWING LAB | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190313911 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $857.93 | 12/31/2025 | Non-covered Recipient Entity UC SAN DIEGO HEALTH BLOOD DRAWING LAB | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190313913 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,080.00 | 12/29/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175443383 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $215,211.68 | 12/10/2025 | Non-covered Recipient Entity Moores Cancer Center-Clinical Trials Office- Genitourinary | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232934943 |
| Principal investigator 1 | Exelixis Inc. | $22,750.00 | 12/08/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380864 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,487.00 | 12/04/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175443210 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,336.00 | 12/04/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175443214 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,950.00 | 12/01/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,475.00 | 11/28/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175443222 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,000.00 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409558 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $13.50 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409572 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.12 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409584 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,819.61 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409588 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $137.90 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409592 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,592.87 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409606 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $270.00 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409608 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,819.61 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409610 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $270.00 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409614 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.12 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409632 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,457.80 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409636 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,457.80 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409644 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $57.50 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409646 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,592.87 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409664 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $57.50 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409672 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $57.50 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409674 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,000.00 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409682 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $111.09 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409704 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,000.00 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409726 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $274.05 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409728 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $182.60 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409736 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,819.61 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409744 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $57.50 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409770 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,819.61 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409778 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $44.55 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409798 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $25.65 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409800 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,457.80 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409826 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,592.87 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409832 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,592.87 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409844 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,000.00 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409848 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $71.51 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409860 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $270.00 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409862 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $21,000.00 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409876 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,457.80 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409886 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $270.00 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409888 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $41.85 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409892 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $187.70 | 11/27/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409896 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,183.00 | 11/21/2025 | Non-covered Recipient Entity University Of California San Diego | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1235992687 |
| Principal investigator 1 | Exelixis Inc. | $18,200.00 | 11/17/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380868 |
| Principal investigator 1 | Exelixis Inc. | $4,550.00 | 11/17/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380872 |
| Principal investigator 1 | Exelixis Inc. | $11,082.50 | 11/17/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380874 |
| Principal investigator 1 | Exelixis Inc. | $107,961.00 | 11/17/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380882 |
| Recipient | PFIZER INC. | $1,400.00 | 11/06/2025 | Covered Recipient Physician | ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727881 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $111,221.22 | 11/05/2025 | Non-covered Recipient Entity Alliance For Clinical Trials In Oncology Foundation | Global Clinical Study Agreement Xofigo A031801 A Phase I II Randomized Trial of Radium 223 and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis RadiCal Claudia | No dispute reported | 06/30/2026 | 1225408922 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $797,490.46 | 11/05/2025 | Non-covered Recipient Entity UC San Diego | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First | No dispute reported | 06/30/2026 | 1232934810 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,909.14 | 11/05/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CA SAN DIEGO | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654842 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $969.57 | 11/05/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CA SAN DIEGO | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176655056 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,550.00 | 11/03/2025 | Non-covered Recipient Entity MEMORIAL SLOAN KETTERING CANCER CEN | MultiModality Therapeutic Approaches to Eliminate Disease in the Prostate and, Separately, in Metastatic Sites | No dispute reported | 06/30/2026 | 1175308654 |
| Principal investigator 1 | Exelixis Inc. | $3,900.00 | 10/31/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385402 |
| Principal investigator 1 | Exelixis Inc. | $36,036.00 | 10/31/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385404 |
| Principal investigator 1 | Exelixis Inc. | $780.00 | 10/31/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385406 |
| Principal investigator 1 | Exelixis Inc. | $2,340.00 | 10/31/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385408 |
| Principal investigator 1 | Janssen Research & Development, LLC | $332.50 | 10/21/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175443422 |
| Principal investigator 1 | Exelixis Inc. | $9,100.00 | 10/20/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380862 |
| Principal investigator 1 | Exelixis Inc. | $16,111.50 | 10/20/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222385434 |
| Recipient | PFIZER INC. | $940.00 | 10/18/2025 | Covered Recipient Physician | ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727727 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,351.41 | 10/15/2025 | Non-covered Recipient Entity UC SAN DIEGO HEALTH BLOOD DRAWING LAB | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190306093 |
| Principal investigator 1 | Exelixis Inc. | $3,965.00 | 10/13/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380860 |
| Principal investigator 1 | Exelixis Inc. | $12,663.34 | 10/13/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380866 |
| Principal investigator 1 | Exelixis Inc. | $107,961.00 | 10/13/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380870 |
| Principal investigator 1 | Exelixis Inc. | $7,550.00 | 10/13/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380878 |
| Principal investigator 1 | Exelixis Inc. | $9,100.00 | 10/13/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380880 |
| Principal investigator 1 | Exelixis Inc. | $107,961.00 | 10/06/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380876 |
| Principal investigator 1 | Janssen Research & Development, LLC | $33,216.67 | 10/06/2025 | Non-covered Recipient Entity MEMORIAL SLOAN KETTERING CANCER CEN | MultiModality Therapeutic Approaches to Eliminate Disease in the Prostate and, Separately, in Metastatic Sites | No dispute reported | 06/30/2026 | 1175309395 |
| Principal investigator 1 | Celgene Corporation | $86,337.00 | 09/30/2025 | Non-covered Recipient Entity The Regents Of The University Of California | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1222306465 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $122.58 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911933 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $107.91 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911935 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $107.91 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911937 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911939 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $148.36 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911965 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911967 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911969 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911971 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911973 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $106.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911975 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911977 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $122.58 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911979 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911981 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911983 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $106.55 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911985 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $106.55 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911987 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911989 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911991 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $106.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911993 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911995 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $148.36 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912001 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912003 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $106.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912005 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $106.55 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912007 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912009 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $85.76 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912011 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912013 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $106.55 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912015 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912017 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912019 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $78.43 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912021 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912023 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $78.43 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912025 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912027 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $78.43 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912029 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912031 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912033 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912035 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912037 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912039 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $107.91 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912041 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $148.36 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912043 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $85.76 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912045 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912047 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912049 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912065 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912067 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912069 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $122.58 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912071 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912073 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912075 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18.39 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912077 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912079 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $85.76 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912081 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912083 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $92.78 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912085 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $148.36 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912087 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $84.08 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912089 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $85.76 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912091 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $107.91 | 09/15/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912095 |
| Principal investigator 1 | Exelixis Inc. | $2,976.00 | 09/11/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385378 |
| Principal investigator 1 | Exelixis Inc. | $3,165.40 | 09/11/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385432 |
| Principal investigator 1 | Exelixis Inc. | $31,850.00 | 09/08/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380852 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,507.70 | 09/04/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912093 |
| Principal investigator 1 | Janssen Research & Development, LLC | $72,006.60 | 09/04/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175443258 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $215,844.48 | 08/31/2025 | Non-covered Recipient Entity Moores Cancer Center-Clinical Trials Office- Genitourinary | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232934947 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $594.56 | 08/28/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912051 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,772.94 | 08/28/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912053 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $594.56 | 08/28/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912055 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,772.94 | 08/28/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912057 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,772.94 | 08/28/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912059 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,772.94 | 08/28/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912061 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $594.56 | 08/28/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912063 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,378.00 | 08/25/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443473 |
| Principal investigator 1 | Exelixis Inc. | $992.00 | 08/18/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385380 |
| Principal investigator 1 | Exelixis Inc. | $1,859.53 | 08/18/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385382 |
| Principal investigator 1 | Exelixis Inc. | $992.00 | 08/06/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385384 |
| Recipient | Novartis Pharmaceuticals Corporation | $237.67 | 08/05/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190293029 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $15,368.69 | 08/01/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CA SAN DIEGO | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641756 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $532.00 | 08/01/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CA SAN DIEGO | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641759 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,902.00 | 07/24/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443336 |
| Principal investigator 1 | Exelixis Inc. | $107,961.00 | 07/21/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380856 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $434,001.50 | 07/14/2025 | Non-covered Recipient Entity HOOSIER CANCER RESEARCH NETWORK | A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with Germline Homologous Recombination Repair Gene Alterations (NePtune) | No dispute reported | 06/30/2026 | 1185549159 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $976.59 | 07/14/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409116 |
| Principal investigator 1 | Exelixis Inc. | $5,720.00 | 07/14/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380850 |
| Principal investigator 1 | Exelixis Inc. | $9,100.00 | 07/14/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380854 |
| Principal investigator 1 | Exelixis Inc. | $10,100.00 | 07/14/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380858 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $41.85 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407848 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $87.74 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407854 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $67.68 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407900 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.12 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407908 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $337.50 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407910 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $71.51 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407928 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.12 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408052 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $74.25 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408080 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $67.50 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408120 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $178.77 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408152 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $167.27 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408332 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $274.05 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408334 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $87.75 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408390 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $32.56 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408400 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,000.00 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408416 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $111.09 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408436 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $13.50 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408456 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $137.90 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408494 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $187.70 | 06/25/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408518 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,048.00 | 06/20/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443307 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,620.00 | 06/20/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443324 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,780.00 | 06/20/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443407 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $988.00 | 06/16/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911961 |
| Principal investigator 1 | Exelixis Inc. | $13,650.00 | 06/09/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380846 |
| Recipient | Novartis Pharmaceuticals Corporation | $2,710.63 | 06/02/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190292207 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $594.56 | 05/28/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911997 |
| Principal investigator 1 | Exelixis Inc. | $40,950.00 | 05/27/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380848 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $3,900.00 | 05/21/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911957 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,170.00 | 05/21/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911959 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $715.00 | 05/21/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911963 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $195.00 | 05/21/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911999 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $346,250.00 | 05/20/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFORNIA | A Pilot Study to Improve Germline Testing in At Risk Patients with Prostate | No dispute reported | 06/30/2026 | 1185549163 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228759894 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,048.00 | 04/28/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443561 |
| Principal investigator 1 | Exelixis Inc. | $10,362.60 | 04/23/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222385430 |
| Recipient | PFIZER INC. | $1,900.00 | 04/22/2025 | Covered Recipient Physician | RELUGOLIX CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228752120 |
| Recipient | PFIZER INC. | $1,900.00 | 04/22/2025 | Covered Recipient Physician | RELUGOLIX CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228771425 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $35,787.40 | 04/21/2025 | Non-covered Recipient Entity University of California San Diego Moores Cancer Center | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies | No dispute reported | 06/30/2026 | 1232931222 |
| Principal investigator 1 | Exelixis Inc. | $107,961.00 | 04/14/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380844 |
| Recipient | PFIZER INC. | $3,200.00 | 04/10/2025 | Covered Recipient Physician | ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769835 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $156,686.68 | 03/31/2025 | Non-covered Recipient Entity HOOSIER CANCER RESEARCH NETWORK | A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with Germline Homologous Recombination Repair Gene Alterations (NePtune) | No dispute reported | 06/30/2026 | 1185549161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,048.00 | 03/27/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443498 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $436.80 | 03/25/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911919 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $4,368.00 | 03/25/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911921 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,170.00 | 03/25/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911923 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $867.10 | 03/25/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911925 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $10,816.00 | 03/25/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911927 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.40 | 03/25/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911929 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $429.00 | 03/25/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911931 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,139.08 | 03/24/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403651 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,321.68 | 03/24/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405608 |
| Principal investigator 1 | Exelixis Inc. | $9,100.00 | 03/17/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380836 |
| Principal investigator 1 | Exelixis Inc. | $4,485.00 | 03/17/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380840 |
| Principal investigator 1 | Exelixis Inc. | $43,693.00 | 03/17/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380842 |
| Principal investigator 1 | Exelixis Inc. | $3,120.00 | 03/14/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222385412 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $23,545.00 | 03/03/2025 | Non-covered Recipient Entity University Of California San Diego | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY) | No dispute reported | 06/30/2026 | 1235992685 |
| Principal investigator 1 | Exelixis Inc. | $5,200.00 | 03/03/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222385416 |
| Principal investigator 1 | Exelixis Inc. | $8,910.00 | 03/03/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222385418 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $594.56 | 02/27/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911915 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $594.56 | 02/27/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911917 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,250.00 | 02/17/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443602 |
| Principal investigator 1 | Exelixis Inc. | $195.00 | 02/14/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222385420 |
| Principal investigator 1 | Exelixis Inc. | $1,950.00 | 02/14/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222385422 |
| Principal investigator 1 | Exelixis Inc. | $3,900.00 | 02/14/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222385424 |
| Principal investigator 1 | Exelixis Inc. | $715.00 | 02/14/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222385426 |
| Principal investigator 1 | Exelixis Inc. | $1,170.00 | 02/14/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222385428 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $105,584.40 | 02/05/2025 | Non-covered Recipient Entity Alliance For Clinical Trials In Oncology Foundation | Global Clinical Study Agreement Xofigo A031801 A Phase I II Randomized Trial of Radium 223 and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis RadiCal Claudia | No dispute reported | 06/30/2026 | 1225402187 |
| Principal investigator 1 | Exelixis Inc. | $1,984.00 | 02/05/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222385354 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,668.00 | 02/03/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFO RNIA | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175443584 |
| Recipient | PFIZER INC. | $620.00 | 02/03/2025 | Covered Recipient Physician | RELUGOLIX CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228753947 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $594.56 | 01/27/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911955 |
| Principal investigator 1 | Exelixis Inc. | $2,600.00 | 01/24/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222385410 |
| Principal investigator 1 | Exelixis Inc. | $3,120.00 | 01/24/2025 | Non-covered Recipient Entity The Regents of the University of California at San Diego | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222385414 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $338.35 | 01/21/2025 | Non-covered Recipient Entity UC San Diego Health La Jolla | A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR214), Versus Nivolumab Alone Versus Standard of Care in Participants With MuscleInvasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible | No dispute reported | 06/30/2026 | 1235992809 |
| Principal investigator 1 | Eli Lilly and Company | $53,259.00 | 01/21/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFORNIA | CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1187888282 |
| Principal investigator 1 | Exelixis Inc. | $4,894.50 | 01/13/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380832 |
| Principal investigator 1 | Exelixis Inc. | $9,100.00 | 01/13/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380834 |
| Principal investigator 1 | Exelixis Inc. | $81,900.00 | 01/13/2025 | Non-covered Recipient Entity Hoosier Cancer Research Network, Inc. | A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1222380838 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $780.00 | 01/08/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911941 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,405.00 | 01/08/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911943 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $10,920.00 | 01/08/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911945 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $3,900.00 | 01/08/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911947 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $10,400.00 | 01/08/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911949 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $594.56 | 01/08/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911951 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,340.00 | 01/08/2025 | Non-covered Recipient Entity The Regents of the University of California | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911953 |